GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Operating Margin %

Radiopharm Theranostics (Radiopharm Theranostics) Operating Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Radiopharm Theranostics's Operating Income for the six months ended in Dec. 2023 was $-16.53 Mil. Radiopharm Theranostics's Revenue for the six months ended in Dec. 2023 was $0.00 Mil. Therefore, Radiopharm Theranostics's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Radiopharm Theranostics's Operating Margin % or its related term are showing as below:

RDPTF' s Operating Margin % Range Over the Past 10 Years
Min: -221288.89   Med: -116553.35   Max: -11817.81
Current: -11817.81


RDPTF's Operating Margin % is ranked worse than
91.24% of 1027 companies
in the Biotechnology industry
Industry Median: -161.82 vs RDPTF: -11817.81

Radiopharm Theranostics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Radiopharm Theranostics's Operating Income for the six months ended in Dec. 2023 was $-16.53 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-27.85 Mil.


Radiopharm Theranostics Operating Margin % Historical Data

The historical data trend for Radiopharm Theranostics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Operating Margin % Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
Operating Margin %
-233,266.67 -11,816.33

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Operating Margin % - - -6,042.64 - -

Competitive Comparison of Radiopharm Theranostics's Operating Margin %

For the Biotechnology subindustry, Radiopharm Theranostics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Operating Margin % falls into.



Radiopharm Theranostics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Radiopharm Theranostics's Operating Margin % for the fiscal year that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=-23.16 / 0.196
=-11,816.33 %

Radiopharm Theranostics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-16.534 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radiopharm Theranostics  (OTCPK:RDPTF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Radiopharm Theranostics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-20-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 06-30-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire 07-10-2022